Epidermal growth factor receptor overexpression and outcomes in early breast cancer: A systematic review and a meta-analysis. (January 2018)

• Record Type: Journal Article
• Authors: Gonzalez-Conchas, Galileo A.; Rodriguez-Romo, Laura; Hernandez-Barajas, David; Gonzalez-Guerrero, Juan F.; Rodriguez-Fernandez, Ivan A.; Verdines-Perez, Adrian; Templeton, Arnoud J.; Ocana, Alberto; Seruga, Bostjan; Tannock, Ian F.; Amir, Eitan; Vera-Badillo, Francisco E.
• Is Part Of: Cancer treatment reviews. Volume 62(2018)
• Page Start: 1
• Page End: 8
• Publication Date: 2018-01
• Subjects: Epidermal growth factor receptor -- Breast cancer -- Meta-analysis; Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2017.10.008
• Languages: English
• ISSNs: 0305-7372

Abstract

Highlights: EGFR overexpression is associated with reduced OS in women with early breast cancer. EGFR overexpression is associated with reduced DFS in women with early breast cancer. The worst effect appears to be greatest in women with triple negative tumors. Abstract: Background: The epidermal growth factor receptor (EGFR) is a member of the ErbB family of membrane tyrosine-kinase receptors. Studies exploring the prognostic role of EGFR-overexpression in early breast cancer have shown variable results, and the true prognostic value of EGFR is unknown. Methods: A systematic review of identified publications exploring the association between EGFR-overexpression (as defined from different techniques and cut-offs) and outcomes [disease-free (DFS) and, overall survival (OS)] in women with early breast cancer. The hazard ratios (HR) for DFS and OS were weighted and pooled in a meta-analysis using generic inverse variance and random effects modeling. Results: Fifty-three studies comprising 21, 418 women were included. EGFR-overexpression was found in 27% of the patients. Primary analysis included studies reporting HRs from multivariable analyses (10 studies including 4857 patients with HRs for OS and 17 studies comprising 8747 patients with HRs for DFS), EGFR-overexpression was associated with worse OS (HR 1.98, 95% CI: 1.59–2.47, p < .001) and DFS (HR 1.59, 95% CI 1.30–1.95, p < .001). The influence of EGFR overexpression on DFS was greater in women with triple negative tumors compared to women with non-triple negative tumors (HR 2.35 versus HR 1.45, respectively; p = .01). Analysis looking at odd ratios for both 5-year and 10-year for DFS and OS showed similar results. Conclusion: EGFR-overexpression appears to be associated with reduced OS and DFS in women with early breast cancer. Patients with triple negative and EGFR-overexpression have poorer OS and DFS than those with triple negative tumors and normal EGFR expression.